Claseprubart is a monoclonal antibody targeting human complement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases.